Investor Relations
Investing in AgeTech
Thank you for your interest in Quadralynx. We are building clinically validated technologies to improve Quality of Life for the millions of Seniors and people living with neurological diseases — and we'd Love to tell you more.
The Opportunity
Why Quadralynx
The global AgeTech market represents a massive and underserved opportunity.
Backed by the National Science Foundation through competitive Phase I and Phase II Small Business Innovation Research awards.
Deep market validation through hundreds of interviews with patients, caregivers, neurologists, and healthcare providers.
Collaborating with leading universities and research institutions to validate and advance our technology.
Investment Thesis
Built on a Strong Foundation
Clinically Validated Technology
Clinical trial Q3 2026 - Our speech and voice biomarker algorithms are developed and validated through rigorous clinical research, not just consumer-grade sensing.
FDA General Wellness + 510(k) Exempt
Our hardware and software meets FDA General Wellness and Clinical Decision Support criteria, enabling a faster path to market.
Experienced Leadership
Our team brings decades of combined experience in neuroscience, machine learning, healthcare operations, and commercialization.
Scalable Platform
Wearables, mobile apps, and monitoring technologies built on a unified data platform — designed to scale across conditions and care settings.
Clinical Trial Q3 2026
A pivotal clinical trial is planned for Q3 2026, a key de-risking milestone on the path to broader commercialization.
Underserved Population
Millions of people living with Parkinson's, Alzheimer's, and related conditions have few technology solutions designed specifically for them.
Our Partners & Affiliates
Interested in Investing?
If you would like to pursue a discussion around investment in Quadralynx, please reach out. We welcome the conversation.